中文版
Founded in September2020,Kunda Biology is a technology-driven enterprise focusing on diversified technological application businesses, including "cell technology R&D stem cell immune cell storage and preparation, organoid cultivation, drug sensitivity testing, health management and diagnostic services".
Corporate Culture:
The company takes "Continuously activating vitality through technology" as its vision, upholds the corporate development mission of "Pioneering for life and health", and takes "Innovation-driven, Collaborative sharing, Customer first, Dedicated responsibility" as the core values of Kunda Biology.
TCR-T therapy (T Cell Receptor-Gene Engineered T Cells) is a T cell therapy involving genetic engineering of T cell receptors. By transducing chimeric antigen receptors (fusing antigen-bind- ing domains with T cellsignaling domains) or TCRα/β heterodimers into ordinary T cells, it enha -nces the affinity of T cell receptors (TCRs) for specifically recognizing tumor-associated antige- ns (TAAs) and boosts the combat capability ofimmune cells. This enables T lymphocytes to effi- ciently re-recognize target cells and exert a potent anti-tumor immune effect in the body. Unlike chemotherapy, TCR-T therapy can rapidly kill tumors while avoiding the delayed effects of vac- cines and T lymphocyte checkpoint therapies. It is primarily used in the treatment of tumors such as melanoma, liver cancer, and ovarian cancer.
CAR-NK cells, namely chimeric antigen receptor-NK (CAR-NK) cells, are designed by imitating CAR-Tcells. Through transgenic engineering, synthetic CAR structures are transcribed into NK cells, which is equivalent to installing a "GPS" device on NK cells. This enables them to retain the functions of NK cells while precisely locking onto specific antigen proteins, leaving crafty cancer cells with nowhere to hide.
CAR-T cell therapy is a novel immunotherapy approach. CAR-T is an abbreviation for chimeric antigen receptor T cells. It uses the patient's own T cells, which are genetically engineered to express a specific receptor, thereby enhancing their ability to target tumor cells.
Tumor-infiltrating lymphocyte (TIL) therapy has been a major breakthrough in the field of ca- ncer treatment in recent years. As a novel cellular immunotherapy, TIL therapy attacks tumor cells by ut-ilizing the patient's own immune cells, featuring high specificity and safety.
Email address:kd@kundacell.com
Tel/WeChat：17156961978
Headquarters Address:No. 1168 Chunrong West Road, Yuhua Street,
Chenggong District, Kunming City, Yunnan
